PharmAla Biotech Holdings, Inc. ( (TSE:MDMA) ) just unveiled an update.
PharmAla Biotech Holdings Inc. has entered into an advisory agreement with shareholder Matthew Azrieli, who is expected to aid the company in its expanding U.S. clinical trials business and other growth markets. The agreement includes potential performance-based rewards for Azrieli, aimed at bolstering media, market, and investment advisory efforts. This strategic move is likely to enhance PharmAla’s market position and operational growth, particularly in the U.S., potentially benefiting its stakeholders.
More about PharmAla Biotech Holdings, Inc.
PharmAla Biotech Holdings Inc. is a biotechnology firm specializing in the research, development, and manufacture of MDXX class molecules, particularly MDMA. The company addresses the global shortage of clinical-grade MDMA for trials and commercial purposes in specific areas while also developing new drugs within the same class. PharmAla is unique in supplying clinical-grade MDMA for treatments outside of clinical trials, and it emphasizes regulatory excellence.
Average Trading Volume: 419,405
Technical Sentiment Consensus Rating: Sell
See more insights into MDMA stock on TipRanks’ Stock Analysis page.